ArticleIranian journal of pharmaceutical research : IJPR2015
Mutagenic Effects of Nanosilver Consumer Products: a new Approach to Physicochemical Properties.
Article in Iranian journal of pharmaceutical research : IJPR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 10 citations in OpenAlex.
- Antimutagenic and anticoagulant therapeutic effects of Ag/AgFrontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serious concerns have been expressed about potential health risks of Nano silver containing consumer products (AgNPs) therefore regulatory health risk assessment on such nanoparticles has become mandatory for the safe use of AgNPsinbiomedicalproducts with special concerns to the mutagenic potentials. In this study, we examined the inhibitory and mutagenicity effects of AgNPs in three different sizes of three colloidal AgNPs by Minimal Inhibitory concentration (MIC), Minimal Bactericidal Concentration (MBC) and Bacterial Reverse Mutation Assay (Ames test).All samples were characterized by transmission electron microscopy (TEM), X-Ray Diffraction (XRD) and Dynamic Light Scattering (DLS). DLS analysis showed lack of large agglomeration of the AgNPs and TEM results showed the spherical AgNPswith the average sizes of 15, 19.6, 21.8 nms. Furthermore the XRD analysis showed the crystalline samples with a face centered cubic structure of pure silver.AmestestresultsonColloidal silver nanoparticles showed lack of any mutation in TA100, TA98, YG1029S. typhymuriumstrains.In addition colloidal silver nanoparticles reduced the mutation ratesin all three strains in a concentration dependent manner .This finding creates a new issue in the possible antimutagenic effects of colloidal AgNPsas a new pharmaceutical productwhich should be consideredinfuture studiesby focusing onthephysicochemical properties of AgNPs.
Identifiers
26664384PMC4673945W1777584167What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.